Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Recruiting N/A Interventional Study
Non-alcoholic Fatty Liver Disease (NAFLD) Alcoholic Liver Disease (ALD) Liver Fibrosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 80
Sex
Any
Study type
Interventional
Purpose
Screening
Participants needed
1,788 (estimated)
Sponsor
University Hospital, Angers · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * NAFLD and/or ALD patient defined by at least 1 of the following criteria: * Excessive alcohol consumption: higher than 210 g / week (men), or 140 g / week (women) * Type 2 diabetes * at least 2 metabolic factors among BMI higher than or equal to 25 kg / m 2; Elevated bl…
Contacts

William BELLANGER, PH

02 41 73 58 10

william.bellanger@univ-angers.fr

CONTACT

Marc De Saint Loup

0241357812

madesaintloup@chu-angers.fr

CONTACT